SOURCE: Actinium Pharmaceuticals

Actinium Pharmaceuticals

April 22, 2015 07:00 ET

Actinium to Partner With Aplastic Anemia & MDS International Foundation Patient and Family Forums

Scientific Advisory Board Member Dr. Sergio Giralt to Lead Bone Marrow Transplant Educational Sessions

NEW YORK, NY--(Marketwired - April 22, 2015) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is partnering with the Aplastic Anemia & MDS International Foundation, a leading non-profit health organization, to present educational forums to patients and their families on bone marrow transplant, MDS, aplastic anemia and PNH.

The next AA&MDSIF Patient and Family Conference will take place in Cleveland, Ohio at the Cleveland Airport Marriott on Saturday May 2, 8:30am-5:00pm.

Sergio Giralt, MD, Chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, and Actinium Scientific Advisory Board Member, will present "Understanding BMT, Before and During" and "Bone Marrow Transplant: Managing Post BMT Health and Support" as part of the bone marrow transplant educational track. Additional conferences will take place throughout 2015 in San Francisco, Boston, Chicago and Tampa with a variety of distinguished speakers.

About Bone Marrow Transplant
Bone marrow transplants (BMT) are used to treat a variety of hematologic conditions including leukemia and MDS. BMT involves first clearing a patient's body of his or her own immune cells and then transplanting bone marrow, the source of all blood- and immune-forming cells, from a tissue-matched donor. The new cells, which are free of cancer, repopulate the patient's bone marrow and eventually give rise to a functioning set of blood and immune cells, providing a lifelong cure. BMT offers the chance of a "curative" outcome (2+ year survival), and therefore can play a central role in the treatment of acute myeloid leukemia (AML). The impact of BMT on AML continues to increase with AML being the most common and fastest growing indication for allogeneic BMT, comprising 25% to 30% of all BMT recipients. There are currently over 100,000 BMT survivors across all indications and this number is expected to increase to 250,000 by 2020 and 500,000 by 2030, with 25% of them over age 60.

About AAMDS International Foundation
The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), acute myeloid leukemia (AML) and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world. It is a patient-focused, patient-centered organization, serving patients and families throughout the three phases of bone marrow failure diseases: the life changing phase of diagnosis, the life threatening phase of treatment and the lifelong phase of living with disease.

About Iomab-B™
Iomab-B™ is being developed to prepare patients for hematopoietic stem cell transplantation (HSCT) and will enter a single, pivotal Phase 3 clinical study in relapsed/refractory AML. Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML).

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information